Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(5 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(3 months ago) | |
US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(3 months from now) | |
US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(5 years from now) |
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic